OncoMatch/Clinical Trials/NCT06201247
Off-the-shelf CD123 CAR-NK for R/R AML
Is NCT06201247 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies JD123 for acute myeloid leukemia, in relapse.
Treatment: JD123 — This is a single-centre, single-arm, open-label, first-in-human (FIH) study to evaluate the safety, tolerability and preliminary efficacy of universal Off-the-shelf CAR-NK cells targeted CD123 (JD123 injection) in the treatment of refractory or relapsed CD123-positive acute myeloid leukemia (AML).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: IL3RA overexpression (definitively positive for CD123 by immunohistochemistry or Flow cytometry)
definitively positive for CD123
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic corticosteroids
Exception: inhaled corticosteroids
Systemic use of hormones within 4 weeks prior to enrollment (except for patients with inhaled corticosteroids)
Lab requirements
Kidney function
serum creatinine≤1.5×uln or creatinine clearance rate ≥30ml/min
Liver function
alt≤3×uln, ast≤3×uln, total bilirubin≤2×uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06201247 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic corticosteroids disqualifies patients from enrollment.
Does this trial require IL3RA?
Yes, IL3RA overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages